Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-F019 in Healthy Subjects
NCT04851444Phase 1Completed
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-F019 in coronavirus disease 2019 (COVID-19), sponsored by Biokin Pharmaceutical. Primary endpoint: Serious Adverse Events at 29 days. Started Mar 2021; status: completed.
02
Drugs
SI-F019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04851444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851444.